Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages iv96-iv104

  Schutte, Elise ^a   Gansevoort, Ron T ^a   Benner, Jacqueline ^b   Lutgers, Helen L ^a   Lambers Heerspink, Hiddo J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Biomarker Design Forschungs GmbH   (Austria)

Author keywords

biomarkers; chronic renal failure; diabetes mellitus; diabetic kidney disease; diabetic nephropathy

Indexed keywords

BIOLOGICAL MARKER;

CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; METHODOLOGY; PANEL STUDY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STUDY DESIGN; DIABETIC NEPHROPATHIES; METABOLISM;

BIOMARKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS;

EID: 84939619450     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv119     Document Type: Review

References (31)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
2. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154
3. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673
4. Parving HH, Persson F, Rossing P. Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 2014; 107: 1-8
5. Pena MJ, de Zeeuw D, Mischak H et al. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol Dial Transplant 2015; 30 (Suppl 4): iv86-iv95
6. Pena MJ, Heinzel A, Heinze G et al. A novel panel of biomarkers to predict eGFR decline in type 2 diabetes. PLoS ONE 2015; 10: e0120995
7. Agarwal R, Duffin KL, Laska DA et al. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 2014; 29: 2293-2302
8. Verhave JC, Bouchard J, Goupil R et al. Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: a prospective study. Diabetes Res Clin Pract 2013; 101: 333-340
9. Wong MG, Perkovic V, Woodward M et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int 2013; 83: 278-284
10. Schlatzer D, Maahs DM, Chance MR et al. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care 2012; 35: 549-555
11. Desai AS, Toto R, Jarolim P et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011; 58: 717-728
12. Kern EF, Erhard P, Sun W et al. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 2010; 55: 824-834
13. Astrup AS, Tarnow L, Pietraszek L et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008; 31: 1170-1176
14. Persson F, Rossing P, Hovind P et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-738
15. Hlatky MA, Greenland P, Arnett DK et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416
16. Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment. https://www.syskid.eu; (31 December 2004, date last accessed)
17. Levey AS, Inker LA, Matsushita K et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64: 821-835
18. Lambers Heerspink HJ, Kropelin TF, Hoekman J et al. on behalf of the, Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 2014
19. Prassas I, Brinc D, Farkona S et al. False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin Chem 2014; 60: 381-388
20. Nauta FL, Bakker SJ, Lambers Heerspink H et al. Effect of frozen storage on urinary concentration of kidney damage markers. Am J Kidney Dis 2012; 59: 586-589
21. Brinkman JW, de Zeeuw D, Duker JJ et al. Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin Chem 2005; 51: 2181-2183
22. Harrel FE. Regression Modeling Strategies - with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer, 2001
23. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. J R Stat Soc Ser C Appl Stat 1999; 48: 313-329
24. Hellemons ME, Kerschbaum J, Bakker SJ et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet Med 2012; 29: 567-577
25. Pepe MS, Janes H, Longton G et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-890
26. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935
27. Pencina MJ, D'Agostino RB, Pencina KM et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176: 473-481
28. Leening MJ, Vedder MM, Witteman JC et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med 2014; 160: 122-131
29. Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-12
30. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 2014; 35: 1925-1931
31. Kerr KF, Meisner A, Thiessen-Philbrook H et al. Developing risk prediction models for kidney injury and assessing incremental value for novel biomarkers. Clin J Am Soc Nephrol 2014; 9: 1488-1496